LORVIQUA was designed to have improve Blood-Brain Barrier penetration to address the challenge of CNS Progression head on2,3LORVIQUA showed compelling CNS efficacy in patients with and without brain metastases, both in terms of response and duration.1,2,3  Intracranial Overall Response in Patients with measurable CNS lesions at baseline1
Intracranial ORR (N=30)a,b

aIntracranial response was assessed by an independent committee using modified RECIST, version 1.12
bPatients with measurable CNS metastases at baseline.2
Data cutoff: 20 March 2020.2

  • Median IC-DoR: Not estimable (95% Cl, NE-NE) with LORVIQUA vs 10 months (95% Cl, 9-11) with crizotinib1
CNS progression delayed in nearly all LORVIQUA-treated patients at 1 year2 Time to intracranial progression by BICR at 12 months (ITT population, N=296)1,2 Time to intracranial progression by BICR at 12 months (ITT population, N=296)1,2 ReferencesGraph adapted from  Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029

BICR=blinded independent central review; CNS=central nervous system; HR=hazard ratio; IC-DoR=intracranial duration of response; IC-ORR=intracranial objective response rate; ITT=intention to treat.
ReferencesReferences:1. Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics.2. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.
3. Solomon, Bauer at al; Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 2023;11: 354–66
Efficacy
LORVIQUA safety profile
Review the safety Time to intracranial progression by BICR at 12 months (ITT population, N=296)1,2
PP-LOR-IRL-0069 February 2024 Legal Category S1A Further information available on request
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024